ID   306D326.26
AC   CVCL_B0UY
SY   LT1002; Sphingomab
DR   ATCC; SD-5362
DR   Wikidata; Q108819537
RX   Patent=US9163091;
RX   PubMed=19509417;
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized sonepcizumab (LT1009; Asonex) therapeutic antibody candidate for treatment of patients with cancer or ocular diseases.
CC   Monoclonal antibody isotype: IgG1, kappa.
CC   Monoclonal antibody target: ChEBI; CHEBI:37550; Sphingosine 1-phosphate (S1P).
CC   Discontinued: ATCC; SD-5362; true.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
CA   Hybridoma
DT   Created: 23-09-21; Last updated: 02-05-24; Version: 5
//
RX   Patent=US9163091;
RA   Sabbadini R.A., Garland W.A., Hansen G., Swaney J.S., Matteo R.,
RA   Mills G.B., Wojciak J.M.;
RT   "Compositions and methods for binding lysophosphatidic acid.";
RL   Patent number US9163091, 20-Oct-2015.
//
RX   PubMed=19509417; DOI=10.1194/jlr.M900048-JLR200;
RA   O'Brien N., Jones S.T., Williams D.G., Cunningham H.B., Moreno K.,
RA   Visentin B., Gentile A., Vekich J., Shestowsky W., Hiraiwa M.,
RA   Matteo R., Cavalli A., Grotjahn D., Grant M., Hansen G.,
RA   Campbell M.-A., Sabbadini R.A.;
RT   "Production and characterization of monoclonal
RT   anti-sphingosine-1-phosphate antibodies.";
RL   J. Lipid Res. 50:2245-2257(2009).
//